Foundational nanoparticle patents block architecture; formulation patents protect only preparation.
Platform ownership of delivery technology captures more value than formulation contracts do.
Evaluate nanoparticle IP depth and defensibility before committing to peptide delivery partnerships.
Deep nanoparticle IP from inception beats recent formulation stacks for credibility.
Broad early patents on nanoparticle chemistry control this emerging delivery field.
Ask whether the company has delivered multiple distinct cargoes, not just one.
Intranasal nanoparticles bypass systemic barriers that injectable formulations cannot overcome.
Lipid nanoparticles lead nose-to-brain delivery, but PLGA suits demanding biologics.
How nausea evolves from side effect into learned aversion driving treatment dropout.
Slower dosing and dietary changes help GLP-1 patients tolerate nausea during treatment.
Nasal peptide delivery bypasses the blood-brain barrier through direct neural pathways.
